Brief: Linc Invests In Oncorena's Phase I/II Study Of Orellanine

Linc AB

23/12/2021 07:11

Dec 23 (Reuters) - Linc AB  LIC.ST :
    * LINC INVESTS IN ONCORENA'S PHASE I / II STUDY OF
ORELLANINE FOR
THE TREATMENT OF ADVANCED KIDNEY CANCER
    * THE INVESTMENTS ARE BASED ON PRE-MONEY VALUATION OF SEK
120
MILLION
    * LINC'S INVESTMENT IN FIRST PART OF THE PHASE THE I / II
STUDY
AMOUNTS TO ABOUT SEK 28.9 MILLION AND INVESTMENT IN IT THE
SECOND PART OF THE STUDY AMOUNTS TO ABOUT SEK 41.1 MILLION
    * PROVIDED THAT BOTH FINANCING IS CARRIED OUT, LINC'S TOTAL
INVESTMENT WILL BE SEK 70 MILLION AND RESULTS IN OWNERSHIP SHARE
OF JUST OVER 20% AFTER FULL DILUTION FROM FUTURE INCENTIVE
PROGRAMS

Source text for Eikon:  ID:nMFN8yT3dY 
Further company coverage:  LIC.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 6600;))